Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2015, Article ID 350324, 9 pages
http://dx.doi.org/10.1155/2015/350324
Clinical Study

High Intensity Focused Ultrasound versus Brachytherapy for the Treatment of Localized Prostate Cancer: A Matched-Pair Analysis

1Department of Urology, Jules Bordet Institute, Université Libre de Bruxelles, 1000 Brussels, Belgium
2Department of Urology, Erasme Hospital, Université Libre de Bruxelles, 1070 Brussels, Belgium

Received 4 March 2015; Accepted 9 June 2015

Academic Editor: Nazareno Suardi

Copyright © 2015 Fouad Aoun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Nicholas Lukens, M. Gamez, K. Hu, and L. B. Harrison, “Modern brachytherapy,” Seminars in Oncology, vol. 41, no. 6, pp. 831–847, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. B. J. Davis, E. M. Horwitz, W. R. Lee et al., “American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy,” Brachytherapy, vol. 11, no. 1, pp. 6–19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. N. N. Stone and R. G. Stock, “Complications following permanent prostate brachytherapy,” European Urology, vol. 41, no. 4, pp. 427–433, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Gupta and C. A. Narayan, “Image-guided radiation therapy: physician's perspectives,” Journal of Medical Physics, vol. 37, no. 4, pp. 174–182, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Giberti, L. Chiono, F. Gallo, M. Schenone, and E. Gastaldi, “Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study,” World Journal of Urology, vol. 27, no. 5, pp. 607–612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. H. P. Beerlage, G. J. L. H. van Leenders, G. O. N. Oosterhof et al., “High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study,” Prostate, vol. 39, no. 1, pp. 41–46, 1999. View at Google Scholar · View at Scopus
  7. L. Dickinson, Y. Hu, H. U. Ahmed et al., “Image-directed, tissue-preserving focal therapy of prostate cancer: a feasibility study of a novel deformable magnetic resonance-ultrasound (MR-US) registration system,” BJU International, vol. 112, no. 5, pp. 594–601, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Biermann, R. Montironi, A. Lopez-Beltran, S. Zhang, and L. Cheng, “Histopathological findings after treatment of prostate cancer using high-intensity focused ultrasound (HIFU),” Prostate, vol. 70, no. 11, pp. 1196–1200, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Ryan, A. Finelli, N. Lawrentschuk et al., “Prostatic needle biopsies following primary high intensity focused ultrasound (HIFU) therapy for prostatic adenocarcinoma: histopathological features in tumour and non-tumour tissue,” Journal of Clinical Pathology, vol. 65, no. 8, pp. 729–734, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Madersbacher, M. Pedevilla, L. Vingers, M. Susani, and M. Marberger, “Effect of high-intensity focused ultrasound on human prostate cancer in vivo,” Cancer Research, vol. 55, no. 15, pp. 3346–3351, 1995. View at Google Scholar · View at Scopus
  11. A. Gelet, J. Y. Chapelon, R. Bouvier et al., “Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience,” European Urology, vol. 29, no. 2, pp. 174–183, 1996. View at Google Scholar · View at Scopus
  12. K. Limani, F. Aoun, S. Holz, M. Paesmans, A. Peltier, and R. van Velthoven, “Single high intensity focused ultrasound session as a whole gland primary treatment for clinically localized prostate cancer: 10-year outcomes,” Prostate Cancer, vol. 2014, Article ID 186782, 7 pages, 2014. View at Publisher · View at Google Scholar
  13. A. V. D'Amico, R. Whittington, S. Bruce Malkowicz et al., “Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer,” Journal of the American Medical Association, vol. 280, no. 11, pp. 969–974, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Roach III, G. Hanks, H. Thames Jr. et al., “Defining biochemical failure following radiation therapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendation of the RTOG-ASTRO Phoenix Consensus Conference,” International Journal of Radiation Oncology, Biology, Physics, vol. 65, pp. 965–974, 2006. View at Google Scholar
  15. A. Blana, S. C. W. Brown, C. Chaussy et al., “High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure,” BJU International, vol. 104, no. 8, pp. 1058–1062, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Dindo, N. Demartines, and P.-A. Clavien, “Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey,” Annals of Surgery, vol. 240, no. 2, pp. 205–213, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Mitropoulos, W. Artibani, M. Graefen, M. Remzi, M. Rouprêt, and M. Truss, “Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations,” European Urology, vol. 61, no. 2, pp. 341–349, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. T. A. Stamey, “Endoscopic suspension of the vesical neck for urinary incontinence,” Surgery Gynecology and Obstetrics, vol. 136, no. 4, pp. 547–554, 1973. View at Google Scholar · View at Scopus
  19. R. Ganzer, C. N. Robertson, J. F. Ward et al., “Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria—analysis from the @-Registry,” BJU International, vol. 108, no. 8, pp. E196–E201, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. J. H. Pinthus, F. Farrokhyar, M. M. Hassouna et al., “Single-session primary high-intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation-based technology,” BJU International, vol. 110, no. 8, pp. 1142–1148, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. E. R. Cordeiro, X. Cathelineau, S. Thüroff, M. Marberger, S. Crouzet, and J. J. M. C. H. De La Rosette, “High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer,” BJU International, vol. 110, no. 9, pp. 1228–1242, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Uchida, R. O. Illing, P. J. Cathcart, and M. Emberton, “To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate?” BJU International, vol. 98, no. 3, pp. 537–539, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Lukka, T. Waldron, J. Chin et al., “High-intensity focused ultrasound for prostate cancer: a systematic review,” Clinical Oncology, vol. 23, no. 2, pp. 117–127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. S. J. Frank, P. D. Grimm, J. E. Sylvester et al., “Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States,” Brachytherapy, vol. 6, no. 1, pp. 2–8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. R. G. Stock, N. N. Stone, J. A. Cesaretti, and B. S. Rosenstein, “Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results,” International Journal of Radiation Oncology Biology Physics, vol. 64, no. 2, pp. 527–533, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. G. S. Merrick, R. W. Galbreath, W. M. Butler et al., “Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for gleason score 7 prostate cancer,” Cancer, vol. 110, no. 2, pp. 289–296, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. R. G. Stock, J. Berkowitz, S. R. Blacksburg, and N. N. Stone, “Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure,” BJU International, vol. 110, no. 9, pp. 1257–1261, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. N. N. Stone, M. M. Stone, B. S. Rosenstein, P. Unger, and R. G. Stock, “Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy,” Journal of Urology, vol. 185, no. 2, pp. 495–500, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. D. A. Wattson, M.-H. Chen, J. W. Moul et al., “The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection,” International Journal of Radiation Oncology Biology Physics, vol. 82, no. 5, pp. e773–e779, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. EAU, Guidelines on Prostate Cancer, European Association of Urology, 2012.
  31. J. L. Mohler, A. J. Armstrong, R. R. Bahnson et al., “Prostate cancer, version 3.2012: featured updates to the NCCN Guidelines,” Journal of the National Comprehensive Cancer Network, vol. 10, no. 9, pp. 1081–1087, 2012. View at Google Scholar · View at Scopus
  32. A. Y. Ho, R. J. Burri, J. A. Cesaretti, N. N. Stone, and R. G. Stock, “Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy,” International Journal of Radiation Oncology Biology Physics, vol. 75, no. 1, pp. 16–22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. D. S. Elterman, J. Barkin, S. B. Radomski et al., “Results of high intensity focused ultrasound treatment of prostate cancer: early Canadian experience at a single center,” Canadian Journal of Urology, vol. 18, no. 6, pp. 6037–6042, 2011. View at Google Scholar · View at Scopus
  34. A. Blana, S. Rogenhofer, R. Ganzer, P. J. Wild, W. F. Wieland, and B. Walter, “Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer,” World Journal of Urology, vol. 24, no. 5, pp. 585–590, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Crouzet, X. Rebillard, D. Chevallier et al., “Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients,” European Urology, vol. 58, no. 4, pp. 559–566, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. A. U. Kishan and P. A. Kupelian, “Late rectal toxicity after low-dose-rate brachytherapy: incidence, predictors, and management of side effects,” Brachytherapy, vol. 14, no. 2, pp. 148–159, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Wallner, L. Henry, S. Wasserman, and M. Dattoli, “Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection,” International Journal of Radiation Oncology Biology Physics, vol. 37, no. 3, pp. 565–569, 1997. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Budäus, M. Bolla, A. Bossi et al., “Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature,” European Urology, vol. 61, no. 1, pp. 112–127, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Ragde, J. C. Blasko, P. D. Grimm et al., “Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma,” Cancer, vol. 80, no. 3, pp. 442–453, 1997. View at Publisher · View at Google Scholar · View at Scopus
  40. R. M. Benoit, M. J. Naslund, and J. K. Cohen, “Complications after prostate brachytherapy in the Medicare population,” Urology, vol. 55, no. 1, pp. 91–96, 2000. View at Publisher · View at Google Scholar · View at Scopus
  41. T. L. McElveen, F. M. Waterman, H. Kim, and A. P. Dicker, “Factors predicting for urinary incontinence after prostate brachytherapy,” International Journal of Radiation Oncology Biology Physics, vol. 59, no. 5, pp. 1395–1404, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Crouzet, J. Y. Chapelon, O. Rouvière et al., “Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients,” European Urology, vol. 65, no. 5, pp. 907–914, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Boutier, N. Girouin, A. B. Cheikh et al., “Location of residual cancer after transrectal high-intensity focused ultrasound ablation for clinically localized prostate cancer,” BJU International, vol. 108, no. 11, pp. 1776–1781, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. X. Rebillard, M. Soulié, E. Chartier-Kastler et al., “High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology,” BJU International, vol. 101, no. 10, pp. 1205–1213, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. R. Van Velthoven, F. Aoun, K. Limani, K. Narahari, M. Lemort, and A. Peltier, “Primary zonal high intensity focused ultrasound for prostate cancer: results of a prospective phase IIa feasibility study,” Prostate Cancer, vol. 2014, Article ID 756189, 6 pages, 2014. View at Publisher · View at Google Scholar